Home > Publications database > A multidimensional atlas of human glioblastoma-like organoids reveals highly coordinated molecular networks and effective drugs. > print

001     287296
005     20250415112709.0
024 7 _ |a 10.1038/s41698-024-00500-5
|2 doi
024 7 _ |a pmid:38273014
|2 pmid
024 7 _ |a altmetric:158876515
|2 altmetric
037 _ _ |a DKFZ-2024-00216
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Wang, Changwen
|0 P:(DE-He78)be724b82903aa397737196d8200edb30
|b 0
|e First author
|u dkfz
245 _ _ |a A multidimensional atlas of human glioblastoma-like organoids reveals highly coordinated molecular networks and effective drugs.
260 _ _ |a [London]
|c 2024
|b Springer Nature
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1706532584_23420
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a DKFZ-ZMBH alliance / #EA:A240#LA:A240#
520 _ _ |a Recent advances in the genomics of glioblastoma (GBM) led to the introduction of molecular neuropathology but failed to translate into treatment improvement. This is largely attributed to the genetic and phenotypic heterogeneity of GBM, which are considered the major obstacle to GBM therapy. Here, we use advanced human GBM-like organoid (LEGO: Laboratory Engineered Glioblastoma-like Organoid) models and provide an unprecedented comprehensive characterization of LEGO models using single-cell transcriptome, DNA methylome, metabolome, lipidome, proteome, and phospho-proteome analysis. We discovered that genetic heterogeneity dictates functional heterogeneity across molecular layers and demonstrates that NF1 mutation drives mesenchymal signature. Most importantly, we found that glycerol lipid reprogramming is a hallmark of GBM, and several targets and drugs were discovered along this line. We also provide a genotype-based drug reference map using LEGO-based drug screen. This study provides new human GBM models and a research path toward effective GBM therapy.
536 _ _ |a 311 - Zellbiologie und Tumorbiologie (POF4-311)
|0 G:(DE-HGF)POF4-311
|c POF4-311
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
700 1 _ |a Sun, Meng
|b 1
700 1 _ |a Shao, Chunxuan
|0 P:(DE-He78)7e77b1ec44a0797f186de678c66f80a0
|b 2
700 1 _ |a Schlicker, Lisa
|b 3
700 1 _ |a Zhuo, Yue
|0 P:(DE-He78)24e61e2f659895c9e6d595647a29bf36
|b 4
|u dkfz
700 1 _ |a Harim, Yassin
|0 P:(DE-He78)044b8e7cc52bce80fe9afd70f8f4d44e
|b 5
|u dkfz
700 1 _ |a Peng, Tianping
|b 6
700 1 _ |a Tian, Weili
|0 P:(DE-He78)013c1f7493419ce6a1a10fd28abb172b
|b 7
|u dkfz
700 1 _ |a Stöffler, Nadja
|0 P:(DE-He78)79d514e9270d1a0c8b17992db50542f1
|b 8
|u dkfz
700 1 _ |a Schneider, Martin
|0 P:(DE-He78)0d37cc734b95fed555f2244d6fee6320
|b 9
|u dkfz
700 1 _ |a Helm, Dominic
|0 P:(DE-He78)daaed5a5b968028e6e95d273150d5ab1
|b 10
|u dkfz
700 1 _ |a Chu, Youjun
|b 11
700 1 _ |a Fu, Beibei
|b 12
700 1 _ |a Jin, Xiaoliang
|b 13
700 1 _ |a Mallm, Jan-Philipp
|0 P:(DE-He78)697cb039ca08f3b7e5a2a52dbf020b46
|b 14
|u dkfz
700 1 _ |a Mall, Moritz
|0 P:(DE-He78)cb70d67b37a3b9239e352b7fbead37f5
|b 15
|u dkfz
700 1 _ |a Wu, Yonghe
|b 16
700 1 _ |a Schulze, Almut
|0 P:(DE-He78)94ae391f53fb9285e1b68f9930615af1
|b 17
|u dkfz
700 1 _ |a Liu, Haikun
|0 P:(DE-He78)76aeb2431f7458c9261e69c5420390c6
|b 18
|e Last author
|u dkfz
773 _ _ |a 10.1038/s41698-024-00500-5
|g Vol. 8, no. 1, p. 19
|0 PERI:(DE-600)2891458-2
|n 1
|p 19
|t npj precision oncology
|v 8
|y 2024
|x 2397-768X
856 4 _ |u https://inrepo02.dkfz.de/record/287296/files/s41698-024-00500-5.pdf
856 4 _ |u https://inrepo02.dkfz.de/record/287296/files/s41698-024-00500-5.pdf?subformat=pdfa
|x pdfa
909 C O |o oai:inrepo02.dkfz.de:287296
|p VDB
|p OpenAPC
|p openCost
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)be724b82903aa397737196d8200edb30
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)7e77b1ec44a0797f186de678c66f80a0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)24e61e2f659895c9e6d595647a29bf36
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)044b8e7cc52bce80fe9afd70f8f4d44e
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-He78)013c1f7493419ce6a1a10fd28abb172b
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 8
|6 P:(DE-He78)79d514e9270d1a0c8b17992db50542f1
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 9
|6 P:(DE-He78)0d37cc734b95fed555f2244d6fee6320
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-He78)daaed5a5b968028e6e95d273150d5ab1
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 14
|6 P:(DE-He78)697cb039ca08f3b7e5a2a52dbf020b46
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 15
|6 P:(DE-He78)cb70d67b37a3b9239e352b7fbead37f5
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 17
|6 P:(DE-He78)94ae391f53fb9285e1b68f9930615af1
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 18
|6 P:(DE-He78)76aeb2431f7458c9261e69c5420390c6
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-311
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Zellbiologie und Tumorbiologie
|x 0
914 1 _ |y 2024
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NPJ PRECIS ONCOL : 2022
|d 2023-10-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-10-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2023-04-12T15:13:05Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2023-04-12T15:13:05Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2023-04-12T15:13:05Z
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2023-04-12T15:13:05Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-10-27
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-10-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-10-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2023-10-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-10-27
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b NPJ PRECIS ONCOL : 2022
|d 2023-10-27
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2023-10-27
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2023-10-27
915 p c |a APC keys set
|2 APC
|0 PC:(DE-HGF)0000
915 p c |a Local Funding
|2 APC
|0 PC:(DE-HGF)0001
915 p c |a DFG OA Publikationskosten
|2 APC
|0 PC:(DE-HGF)0002
915 p c |a DOAJ Journal
|2 APC
|0 PC:(DE-HGF)0003
920 2 _ |0 I:(DE-He78)A240-20160331
|k A240
|l A240 Molekulare Neurogenetik
|x 0
920 0 _ |0 I:(DE-He78)A240-20160331
|k A240
|l A240 Molekulare Neurogenetik
|x 0
920 1 _ |0 I:(DE-He78)A240-20160331
|k A240
|l A240 Molekulare Neurogenetik
|x 0
920 1 _ |0 I:(DE-He78)W120-20160331
|k W120
|l Proteomics
|x 1
920 1 _ |0 I:(DE-He78)W192-20160331
|k W192
|l scOpen Lab
|x 2
920 1 _ |0 I:(DE-He78)A340-20160331
|k A340
|l A340 NWG Engeneering von Zellidentitäten und Krankheitsmodellen
|x 3
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)A240-20160331
980 _ _ |a I:(DE-He78)W120-20160331
980 _ _ |a I:(DE-He78)W192-20160331
980 _ _ |a I:(DE-He78)A340-20160331
980 _ _ |a UNRESTRICTED
980 _ _ |a APC

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21